Clinical Trial Update: Sacituzumab Govitecan In TNBC [Phase 2]

View source ↗

Summary

Phase 2 study of Sacituzumab Govitecan in triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Invasive Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Trodelvy (sacituzumab govitecan) (sacituzumab govitecan)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING